One potential 'cautious' point...9 Feb 2021 10:50
IF the pandemic continues to significantly disrupt healthcare
systems in to H2, there is the possibility of another EPS downgrade.
GSK have clearly flagged this up in the FY guidance.
Now you can make a case this is already in the price,
but perhaps worth staying mindful of.
For GSK, the end of the Covid-19 pandemic can not come soon enough.
And the same applies for the rest of us!.